Cosmo plots $107M IPO for skin business; Bluebird picks a new CSO;

@FierceBiotech: Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Bluebird bio builds its case for gene therapy as first sickle cell patient responds. Article | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> Italy's Cosmo Pharmaceuticals is planning to spin off its dermatology business, Cassiopea, in a European IPO. The drugmaker expects to raise more than 100 million Swiss francs ($107 million) in the deal, Chief Financial Officer Christoph Tanner told Bloomberg. Anything less and "I would fire myself and everybody else," he said. News

> Bluebird bio ($BLUE) has recruited Philip Gregory, former Sangamo BioSciences ($SGMO) chief scientific officer, to take the same position on its staff. More

> The FDA accepted Teva's ($TEVA) application for reslizumab, an antibody designed to treat severe asthma, and promises to make a final decision on the injection by March 2016. GlaxoSmithKline's ($GSK) similar mepolizumab is up for approval by Nov. 4. Item

Medical Device News

@FierceMedDev: ICYMI Friday: Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI Friday: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: India's PM is facing pushback from MSF over access to generic drugs. More from Reuters| Follow @EmilyWFierce

> FDA approves St. Jude's neurostimulator for Parkinson's, setting up rivalry with Medtronic. Report

> Milestone Pharma raises $17M Series B for Phase II of at-home, drug-device cardiac arrhythmia combo. Story

> Study: Researchers find dual-hormone artificial pancreas best for treating nocturnal hypoglycemia. Article

Pharma News

@FiercePharma: G7 vows to combat antibiotics resistance, but animal health groups urge caution. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce:  | Follow @EricPFierce

@CarlyHFierce: ICYMI: Consumer group demands FDA correct 'compounded mistake' on Vanda's Hetlioz label. Report | Follow @CarlyHFierce

> Branded pharma worries, generics makers cheer as trade pact hits snag in Congress. Article

> FDA taps PatientsLikeMe to harness patient info for drug-safety monitoring. News

Animal Health News

> AB Science struggles to break out as canine cancer drug flounders. Report

> Rapamycin raises $2.5M to advance lead drug for treating cancer in pets. Item

> G7 vows to combat antibiotics resistance, but animal health groups urge caution. More

> Scientists scrambling to determine if virulent avian flu is airborne. Story

> Lilly quashes rumors of Elanco spinoff as stock soars. Article

Biotech IT News

> EHR-enabled data dive links stomach blockbusters to heart attacks. More

> Allergan slashes laptop use in full-throttle mobile push. Report

> Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact. Story

> The search for exceptional responders in tumor sequencing databases. Item

> J&J teams with Emulate to use organ-on-a-chip technology in R&D programs. Article

Pharma Marketing News

> PatientsLikeMe, FDA partner up to track online drug safety clues. Item

> CoheroHealth's 'smart,' mobile spirometer begins pilots with pharma, payers. News

> Experts urge FDA to step in to quash 'Low-T' awareness efforts. More

> Merck ramps up Belsomra marketing, hoping to wake up a sleepy insomnia market. Story

> Mannkind investors skittish after CEO, CFO update on Afrezza launch. Article